• SEC Filings

On March 15, 2018, Ionis Pharmaceuticals, Inc. (the “Company”) issued a press release announcing that the Company has entered into an exclusive, worldwide licensing agreement with Akcea Therapeutics, Inc., an affiliate of the Company, for the development and commercialization of inotersen and AKCEA-TTR-L_RX, formerly IONIS-TTR-L_RX.

A copy of this press release is attached as Exhibit 99.1 to this Current Report and incorporated herein by reference.

IONIS PHARMACEUTICALS INC Exhibit
EX-99.1 2 ex99_1.htm EXHIBIT 99.1 Exhibit 99.1     Ionis and Akcea Partner to Commercialize Inotersen for hATTR Ionis licenses to Akcea worldwide rights to inotersen and IONIS-TTR-LRx Collaboration advances commercial readiness for planned mid-2018 inotersen launch,…
To view the full exhibit click here

About IONIS PHARMACEUTICALS, INC. (NASDAQ:IONS)

Ionis Pharmaceuticals, Inc., formerly Isis Pharmaceuticals, Inc., is engaged in discovering and developing ribonucleic acid-targeted (RNA-targeted) therapeutics. The Company operates through two segments: Ionis Core and Akcea Therapeutics. The Company’s Ionis Core segment is developing a drug discovery platform. The Company’s Akcea Therapeutics segment consists of the operations of its subsidiary, Akcea Therapeutics, Inc., which develops and commercializes drugs for cardiometabolic disorders. The Company is developing transformational drugs, which include nusinersen, IONIS-TTR and volanesorsen that are designed to treat patients with orphan diseases. In addition to its Phase III programs, the Company has a pipeline of drugs in Phase II development, which includes IONIS-FXI and IONIS-APO(a)-L. Its Phase II pipeline includes drugs to treat patients with severe and rare diseases, viral infections, ocular diseases, metabolic disorders and cardiovascular diseases.